Evidence map›Paper›PMID 42400795›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Antisense Oligonucleotide-Mediated Chimeric RNA Knockdown.

Anam Tajammal, Katie Do, Hui Li

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anam TajammalDepartment of Pathology, University of Virginia, Charlottesville, VA, USA.
Katie DoDepartment of Pathology, University of Virginia, Charlottesville, VA, USA.
Hui LiDepartment of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, USA. hl9r@virginia.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Knockdown assays aim to silence the expression of a target gene. By reducing expression of a gene, researchers can investigate the gene's function in biological processes. Common knockdown assays use RNA interference (RNAi) to reduce gene expression by degrading its mRNA. However, RNAi requires the use of double-stranded RNA to target mature mRNA transcripts. Antisense oligonucleotides (ASO) offer an alternative pathway to knocking down gene expression by allowing the use of single-stranded DNA or RNA to target pre-mRNA, mature mRNA, long non-coding RNAs or DNA. Here, we have provided guidelines and procedures for ASO knockdown, application to chimeric RNAs, and necessary controls for a successful experiment.

Indexed as

Gene Knockdown TechniquesOligonucleotides, AntisenseAnimalsHumansRNA InterferenceRNA, MessengerRNA, Small InterferingOligonucleotides, AntisenseRNA, MessengerRNA, Small InterferingAntisense oligonucleotideChimeric RNAInterfering RNA (RNAi)Knockdown

Identifiers

PMID42400795

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.